"Within the field of TAVI, delivery systems often don't receive the attention of the evolving technology of the valves themselves, but improvements to a delivery system can result in substantial benefits to patients," said Neil Moat, M.D., chief medical officer of Abbott's structural heart business and a physician who has performed several hundred TAVI procedures. "If we look at the total TAVI procedure, innovation around both the valve itself and also how it's delivered during an implant are both central to improving outcomes."
The Portico Transcatheter Aortic Valve and FlexNav Delivery System are approved for investigational use only in the U.S.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The Navitor Transcatheter Aortic Valve is Abbott's next generation TAVI valve, currently under investigation in the United States. The Navitor valve is approved only for investigational use.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
SOURCE Abbott
Back to HCB News
